Related coverage linked through entity extraction aliases.
Mar 01, 2026
Anbio Biotechnology shares gained following an upgrade from a sell rating to hold. The company reported $0.04 earnings per share and $2.29 million in quarterly revenue.
Mar 01, 2026
Inovio Pharmaceuticals trades as a speculative micro-cap biotech on NASDAQ, with DNA medicine candidates in oncology and infectious disease facing binary clinical risks and ongoing capital needs.
Feb 27, 2026
The American Medical Association and University of Minnesota's Vaccine Integrity Project are creating an independent vaccine review system after major changes at the CDC raised concerns among public health experts.
Feb 27, 2026
Moderna announced UK authorization for its updated Spikevax vaccine targeting the LP.8.1 variant and European Commission marketing authorization for mNEXSPIKE, its third vaccine approved in the EU.
Feb 23, 2026
A multicenter study of over 500 children found no differences in neurodevelopmental outcomes between offspring of mothers who received mRNA COVID-19 vaccines during pregnancy and those who did not.
Feb 25, 2026
A Lancet study of 1.1 million people found that 65% of those initially hesitant about COVID-19 vaccines went on to get vaccinated, with concerns about mRNA technology and safety declining as evidence accumulated during the rollout.
Feb 24, 2026
Ralph Abraham resigned as CDC principal deputy director after less than two months, leaving the agency's top two positions vacant. The departure is part of broader HHS leadership changes under Secretary Robert F. Kennedy Jr.
Feb 23, 2026
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging the company's newly approved mNEXSPIKE vaccine uses proprietary mRNA technology without authorization.
Feb 23, 2026
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
Feb 17, 2026
Moderna faces a pivotal transition from pandemic-era revenues to a diversified mRNA portfolio, with recent regulatory setbacks offset by strong RSV vaccine performance and upcoming Phase 3 oncology readouts.
Feb 20, 2026
The FDA has approved a supplemental new drug application for the combination regimen of Venclexta (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia, supported by Phase 3 AMPLIFY trial data.
Feb 20, 2026
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.
Feb 18, 2026
University of Alberta researchers identified GlpG protease as a new drug target for treating antibiotic-resistant E. coli, which causes 250,000 UTI deaths annually. Inhibiting the protease prevented bacterial adhesion and biofilm formation in laboratory tests.
Feb 17, 2026
Moderna posted Q4 2025 revenue of $678 million, beating analyst estimates despite a 29.8% year-over-year decline. The company reduced operating expenses by 31% while facing FDA refusal to file its flu vaccine application.
Feb 11, 2026
Obesity contributes to about 1 in every 4 infectious disease deaths in the United States and 1 in 10 globally, according to a major study. People with obesity face 70% higher risk of hospitalization or death from infections, with risk tripling at severe obesity levels.
Feb 20, 2026
Eli Lilly's Omvoh demonstrated durable efficacy in Crohn's disease, with over 90% of patients maintaining steroid-free clinical remission through three years of monthly treatment in the Phase III VIVID-2 extension study.
Feb 20, 2026
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
Feb 19, 2026
National Institutes of Health Director Jay Bhattacharya will serve as acting director of the Centers for Disease Control and Prevention following Jim O'Neill's departure. Bhattacharya will oversee both agencies simultaneously as the CDC faces significant instability.
Feb 18, 2026
The FDA has reversed its earlier refusal and will now review Moderna's mRNA-based flu vaccine application, with a decision expected by August 5. The company modified its regulatory approach to address concerns about older adults.
Feb 20, 2026
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE violates its mRNA vaccine design patent.
